Nutriband Inc. (NASDAQ:NTRB) Short Interest Down 22.1% in February

Nutriband Inc. (NASDAQ:NTRB) saw a large decrease in short interest in February. As of February 28th, there was short interest totalling 281,200 shares, a decrease of 22.1% from the February 13th total of 361,000 shares. Approximately 5.5% of the company’s shares are short sold. Based on an average daily volume of 204,900 shares, the short-interest ratio is currently 1.4 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nutriband stock. Haven Private LLC acquired a new stake in shares of Nutriband Inc. (NASDAQ:NTRB) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 11,561 shares of the company’s stock, valued at approximately $54,000. Haven Private LLC owned approximately 0.10% of Nutriband as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 19.70% of the company’s stock.

Nutriband Trading Up 4.4 %

Shares of NASDAQ:NTRB traded up $0.28 on Monday, hitting $6.48. The company had a trading volume of 14,982 shares, compared to its average volume of 83,672. The firm’s 50-day simple moving average is $6.55 and its two-hundred day simple moving average is $5.68. Nutriband has a 1 year low of $2.25 and a 1 year high of $11.78. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $71.91 million, a price-to-earnings ratio of -9.12 and a beta of 1.12.

Wall Street Analyst Weigh In

Separately, Noble Financial started coverage on shares of Nutriband in a research report on Wednesday, January 22nd. They set an “outperform” rating and a $13.00 price target for the company.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.